NZ527201A - Stable norastemizole formulations comprising coated norastemizole particles - Google Patents
Stable norastemizole formulations comprising coated norastemizole particlesInfo
- Publication number
- NZ527201A NZ527201A NZ527201A NZ52720198A NZ527201A NZ 527201 A NZ527201 A NZ 527201A NZ 527201 A NZ527201 A NZ 527201A NZ 52720198 A NZ52720198 A NZ 52720198A NZ 527201 A NZ527201 A NZ 527201A
- Authority
- NZ
- New Zealand
- Prior art keywords
- norastemizole
- particles
- coated
- stable
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82447797A | 1997-03-26 | 1997-03-26 | |
US85178697A | 1997-05-06 | 1997-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ527201A true NZ527201A (en) | 2004-12-24 |
Family
ID=27124816
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ52720098A NZ527200A (en) | 1997-03-26 | 1998-03-25 | Stable norastemizole formulations including a super disintegrant |
NZ517472A NZ517472A (en) | 1997-03-26 | 1998-03-25 | Lactose free norastemizole formulations with improved stability |
NZ527201A NZ527201A (en) | 1997-03-26 | 1998-03-25 | Stable norastemizole formulations comprising coated norastemizole particles |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ52720098A NZ527200A (en) | 1997-03-26 | 1998-03-25 | Stable norastemizole formulations including a super disintegrant |
NZ517472A NZ517472A (en) | 1997-03-26 | 1998-03-25 | Lactose free norastemizole formulations with improved stability |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1035869A1 (xx) |
JP (1) | JP2002512614A (xx) |
KR (1) | KR20010005746A (xx) |
CN (1) | CN1257431A (xx) |
AR (1) | AR012187A1 (xx) |
BR (1) | BR9808428A (xx) |
CA (1) | CA2284705A1 (xx) |
HU (1) | HUP0001823A3 (xx) |
NO (1) | NO994655L (xx) |
NZ (3) | NZ527200A (xx) |
RU (1) | RU2214245C2 (xx) |
WO (1) | WO1998042379A2 (xx) |
ZA (1) | ZA982562B (xx) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ289261B6 (cs) * | 2000-07-11 | 2001-12-12 | Léčiva, A.S. | Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby |
EP2201982A1 (en) * | 2008-12-24 | 2010-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Histamine H4 receptor antagonists for the treatment of vestibular disorders |
EP2496217B1 (en) * | 2009-08-24 | 2019-03-27 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Direct compression tablets of otilonium |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0232937B1 (en) * | 1986-02-03 | 1992-08-19 | Janssen Pharmaceutica N.V. | Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines |
DE4037426A1 (de) * | 1990-11-24 | 1992-05-27 | Kali Chemie Pharma Gmbh | Piperidinoalkylbenzoxazin- und -thiazin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
EP1262183A1 (en) * | 1992-09-03 | 2002-12-04 | Sepracor, Inc. | Use of norastemizole for the treatment of allergic rhinitis |
KR19990067622A (ko) * | 1995-11-17 | 1999-08-25 | 게리 디. 스트리트, 스티븐 엘. 네스비트 | 알레르기성 질환의 치료에 유용한 치환된 4-(1h-벤즈이미다졸-2-일-아미노)피페리딘 |
PL191073B1 (pl) * | 1996-08-16 | 2006-03-31 | Schering Corp | Zastosowanie kombinacji antagonistów receptorów histaminowych H1 i H3 |
-
1998
- 1998-03-25 WO PCT/US1998/005701 patent/WO1998042379A2/en not_active Application Discontinuation
- 1998-03-25 NZ NZ52720098A patent/NZ527200A/xx unknown
- 1998-03-25 NZ NZ517472A patent/NZ517472A/en unknown
- 1998-03-25 KR KR1019997008817A patent/KR20010005746A/ko not_active Application Discontinuation
- 1998-03-25 BR BR9808428-3A patent/BR9808428A/pt not_active IP Right Cessation
- 1998-03-25 RU RU99122607/14A patent/RU2214245C2/ru not_active IP Right Cessation
- 1998-03-25 NZ NZ527201A patent/NZ527201A/xx unknown
- 1998-03-25 CA CA002284705A patent/CA2284705A1/en not_active Abandoned
- 1998-03-25 HU HU0001823A patent/HUP0001823A3/hu unknown
- 1998-03-25 CN CN98805457A patent/CN1257431A/zh active Pending
- 1998-03-25 JP JP54589398A patent/JP2002512614A/ja active Pending
- 1998-03-25 EP EP98914283A patent/EP1035869A1/en not_active Withdrawn
- 1998-03-26 AR ARP980101398A patent/AR012187A1/es unknown
- 1998-03-26 ZA ZA982562A patent/ZA982562B/xx unknown
-
1999
- 1999-09-24 NO NO994655A patent/NO994655L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1035869A1 (en) | 2000-09-20 |
AU6868098A (en) | 1998-10-20 |
NO994655L (no) | 1999-11-15 |
AR012187A1 (es) | 2000-09-27 |
JP2002512614A (ja) | 2002-04-23 |
HUP0001823A3 (en) | 2002-04-29 |
CN1257431A (zh) | 2000-06-21 |
RU2214245C2 (ru) | 2003-10-20 |
AU735257B2 (en) | 2001-07-05 |
NO994655D0 (no) | 1999-09-24 |
NZ517472A (en) | 2003-08-29 |
HUP0001823A2 (hu) | 2001-04-28 |
KR20010005746A (ko) | 2001-01-15 |
CA2284705A1 (en) | 1998-10-01 |
ZA982562B (en) | 1998-10-01 |
BR9808428A (pt) | 2000-05-23 |
WO1998042379A3 (en) | 2001-03-01 |
WO1998042379A2 (en) | 1998-10-01 |
NZ527200A (en) | 2004-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9507917A (pt) | Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico | |
ES2178943A1 (es) | Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica. | |
BG103518A (en) | 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives | |
NO944113L (no) | Stabilt, hydratisert cefalosporin-tört pulver for oral suspensjonsformulering | |
CA2098302A1 (en) | Medicaments | |
CZ258896A3 (en) | Morpholine derivatives, process of their preparation and pharmaceutical compositions containing thereof | |
IL133623A0 (en) | Antithrombotic agents | |
IL133627A0 (en) | Antithrombotic agents | |
IL150895A0 (en) | Oral, nasal and pulmonary formulations of copolymer-1 | |
HUP0203870A2 (hu) | Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény | |
CA2059263A1 (en) | Composition comprising the (-) enantiomer of cis-4-amino-1-(2-hydromethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidine-2-one or an enriched composition thereof, and its uses as a pharmaceutical agent | |
CA2356380A1 (en) | Immunosuppressive effects of pteridine derivatives | |
CA2188283A1 (en) | Substituted 1,3-oxathiolanes with antiviral properties | |
BG103947A (en) | Derivatives of 9-oxymerythromycin | |
EP0902789A4 (xx) | ||
DE69925293D1 (de) | Sprühbeschichtete mikropartikel für nadellose spritzen | |
CA2417935A1 (en) | Anti-inflammatory medicament | |
NZ527201A (en) | Stable norastemizole formulations comprising coated norastemizole particles | |
HUP0203226A2 (hu) | Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény | |
AU2173101A (en) | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents | |
HRP20000704B1 (en) | Controlled release peroral compositions of levosimendan | |
ES2145740T3 (es) | Composiciones de factor de crecimiento, preparacion y uso. | |
NZ531813A (en) | Pharmaceutical formulation | |
BG106093A (en) | 14beta-h-sterols, pharmaceutical compositions comprising them and the use of these derivatives for the preparation of meiosis regulating medicaments | |
CA2089143A1 (en) | Growth factor compositions, preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed |